Correlation Between Relmada Therapeutics and Passage Bio

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Relmada Therapeutics and Passage Bio at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Relmada Therapeutics and Passage Bio into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Relmada Therapeutics and Passage Bio, you can compare the effects of market volatilities on Relmada Therapeutics and Passage Bio and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Relmada Therapeutics with a short position of Passage Bio. Check out your portfolio center. Please also check ongoing floating volatility patterns of Relmada Therapeutics and Passage Bio.

Diversification Opportunities for Relmada Therapeutics and Passage Bio

0.21
  Correlation Coefficient

Modest diversification

The 3 months correlation between Relmada and Passage is 0.21. Overlapping area represents the amount of risk that can be diversified away by holding Relmada Therapeutics and Passage Bio in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Passage Bio and Relmada Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Relmada Therapeutics are associated (or correlated) with Passage Bio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Passage Bio has no effect on the direction of Relmada Therapeutics i.e., Relmada Therapeutics and Passage Bio go up and down completely randomly.

Pair Corralation between Relmada Therapeutics and Passage Bio

Given the investment horizon of 90 days Relmada Therapeutics is expected to under-perform the Passage Bio. In addition to that, Relmada Therapeutics is 1.47 times more volatile than Passage Bio. It trades about -0.23 of its total potential returns per unit of risk. Passage Bio is currently generating about -0.17 per unit of volatility. If you would invest  61.00  in Passage Bio on November 28, 2024 and sell it today you would lose (8.00) from holding Passage Bio or give up 13.11% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Relmada Therapeutics  vs.  Passage Bio

 Performance 
       Timeline  
Relmada Therapeutics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Relmada Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of conflicting performance in the last few months, the Stock's primary indicators remain rather sound which may send shares a bit higher in March 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.
Passage Bio 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Passage Bio has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in March 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders.

Relmada Therapeutics and Passage Bio Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Relmada Therapeutics and Passage Bio

The main advantage of trading using opposite Relmada Therapeutics and Passage Bio positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Relmada Therapeutics position performs unexpectedly, Passage Bio can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Passage Bio will offset losses from the drop in Passage Bio's long position.
The idea behind Relmada Therapeutics and Passage Bio pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.

Other Complementary Tools

Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges